External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer

Deans, Zandra C.
Tull, Justyna
Beighton, Gemma
Abbs, Stephen
Robinson, David O.
Butler, Rachel

November 2011

Laboratories are increasingly required to perform molecular tests for the detection of mutations in ...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Fenizia, Francesca
Barberis, Massimo
Marchetti, Antonio
Fontanini, Gabriella
De Rosa, Gaetano
Taddei, Gian Luigi

January 2015

BACKGROUND: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing fo...

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Dequeker, E.
Ligtenberg, M.J.L.
Borght, S. van der
Krieken, J.H. van

January 2011

In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Tack, Véronique
Ligtenberg, Marjolijn JL
Tembuyser, Lien
Normanno, Nicola
Vander Borght, Sara
Han van Krieken, J
Dequeker, Els

March 2015

Regulations for the selection of patients with metastatic colorectal cancer for anti-EGFR treatment ...

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Tack, V.
Ligtenberg, M.J.L.
Tembuyser, L.
Normanno, N.
Borght, S. van der
Krieken, J.H. van
Dequeker, E.M.

January 2015

Contains fulltext : 155246.pdf (publisher's version ) (Closed access)BACKGROUND: R...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, Lien
Ligtenberg, Marjolijn JL
Normanno, Nicola
Delen, Sofie
van Krieken, J Han
Dequeker, Els

May 2014

Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...

RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment

Tack, Véronique
ligtenberg, Marjolijn JL
Siebers, Albert G
Rombout, Paul DM
Dabir, Parag D
Weren, Robbert DA
van Krieken, J Han
Dequeker, Els

January 2018

Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined befo...

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

Bellon, E.
Ligtenberg, M.J.L.
Tejpar, S.
Cox, K.
Hertogh, G. de
Stricker, K.
Edsjo, A.
Gorgoulis, V.
Hofler, G.
Jung, A.
Kotsinas, A.
Laurent-Puig, P.
Lopez-Rios, F.
Hansen, T.P.
Rouleau, E.
Vandenberghe, P.
Krieken, J.H.J.M. van
Dequeker, E.

January 2011

Contains fulltext : 96912.pdf (publisher's version ) (Closed access)The use of epi...

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

Bellon, E.
Ligtenberg, M.J.L.
Tejpar, S.
Cox, K.
Hertogh, G. de
Stricker, K.
Edsjo, A.
Gorgoulis, V.
Hofler, G.
Jung, A.
Kotsinas, A.
Laurent-Puig, P.
Lopez-Rios, F.
Hansen, T.P.
Rouleau, E.
Vandenberghe, P.
Krieken, J.H.J.M. van
Dequeker, E.

January 2011

The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, L.
Ligtenberg, M.J.L.
Normanno, N.
Delen, S.
Krieken, J.H.J.M. van
Dequeker, E.M.

January 2014

Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
Taddei, G. L.
DE ROSA, GAETANO

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
Taddei, G. L.
DE ROSA, GAETANO

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
De Rosa, G.
Taddei, G.L

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Dequeker, E.
Ligtenberg, M.J.L.
Borght, S. van der
Krieken, J.H. van

January 2011

Contains fulltext : 96128.pdf (publisher's version ) (Closed access)In Europe, the...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, L.
Ligtenberg, M.J.L.
Normanno, N.
Delen, S.
Krieken, J.H.J.M. van
Dequeker, E.M.

January 2014

Contains fulltext : 138176.pdf (publisher's version ) (Closed access)Precision med...

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer

Deans, Zandra C.
Tull, Justyna
Beighton, Gemma
Abbs, Stephen
Robinson, David O.
Butler, Rachel

November 2011

Laboratories are increasingly required to perform molecular tests for the detection of mutations in ...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Fenizia, Francesca
Barberis, Massimo
Marchetti, Antonio
Fontanini, Gabriella
De Rosa, Gaetano
Taddei, Gian Luigi

January 2015

BACKGROUND: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing fo...

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Dequeker, E.
Ligtenberg, M.J.L.
Borght, S. van der
Krieken, J.H. van

January 2011

In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Tack, Véronique
Ligtenberg, Marjolijn JL
Tembuyser, Lien
Normanno, Nicola
Vander Borght, Sara
Han van Krieken, J
Dequeker, Els

March 2015

Regulations for the selection of patients with metastatic colorectal cancer for anti-EGFR treatment ...

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Tack, V.
Ligtenberg, M.J.L.
Tembuyser, L.
Normanno, N.
Borght, S. van der
Krieken, J.H. van
Dequeker, E.M.

January 2015

Contains fulltext : 155246.pdf (publisher's version ) (Closed access)BACKGROUND: R...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, Lien
Ligtenberg, Marjolijn JL
Normanno, Nicola
Delen, Sofie
van Krieken, J Han
Dequeker, Els

May 2014

Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...

RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment

Tack, Véronique
ligtenberg, Marjolijn JL
Siebers, Albert G
Rombout, Paul DM
Dabir, Parag D
Weren, Robbert DA
van Krieken, J Han
Dequeker, Els

January 2018

Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined befo...

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

Bellon, E.
Ligtenberg, M.J.L.
Tejpar, S.
Cox, K.
Hertogh, G. de
Stricker, K.
Edsjo, A.
Gorgoulis, V.
Hofler, G.
Jung, A.
Kotsinas, A.
Laurent-Puig, P.
Lopez-Rios, F.
Hansen, T.P.
Rouleau, E.
Vandenberghe, P.
Krieken, J.H.J.M. van
Dequeker, E.

January 2011

Contains fulltext : 96912.pdf (publisher's version ) (Closed access)The use of epi...

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

Bellon, E.
Ligtenberg, M.J.L.
Tejpar, S.
Cox, K.
Hertogh, G. de
Stricker, K.
Edsjo, A.
Gorgoulis, V.
Hofler, G.
Jung, A.
Kotsinas, A.
Laurent-Puig, P.
Lopez-Rios, F.
Hansen, T.P.
Rouleau, E.
Vandenberghe, P.
Krieken, J.H.J.M. van
Dequeker, E.

January 2011

The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, L.
Ligtenberg, M.J.L.
Normanno, N.
Delen, S.
Krieken, J.H.J.M. van
Dequeker, E.M.

January 2014

Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
Taddei, G. L.
DE ROSA, GAETANO

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
Taddei, G. L.
DE ROSA, GAETANO

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, N.
Pinto, C.
Castiglione, F.
Fenizia, F.
Barberis, M.
Marchetti, A.
Fontanini, G.
De Rosa, G.
Taddei, G.L

January 2015

Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Dequeker, E.
Ligtenberg, M.J.L.
Borght, S. van der
Krieken, J.H. van

January 2011

Contains fulltext : 96128.pdf (publisher's version ) (Closed access)In Europe, the...

Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer

Tembuyser, L.
Ligtenberg, M.J.L.
Normanno, N.
Delen, S.
Krieken, J.H.J.M. van
Dequeker, E.M.

January 2014

Contains fulltext : 138176.pdf (publisher's version ) (Closed access)Precision med...

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer

Deans, Zandra C.
Tull, Justyna
Beighton, Gemma
Abbs, Stephen
Robinson, David O.
Butler, Rachel

November 2011

Laboratories are increasingly required to perform molecular tests for the detection of mutations in ...

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Fenizia, Francesca
Barberis, Massimo
Marchetti, Antonio
Fontanini, Gabriella
De Rosa, Gaetano
Taddei, Gian Luigi

January 2015

BACKGROUND: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing fo...

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Dequeker, E.
Ligtenberg, M.J.L.
Borght, S. van der
Krieken, J.H. van

January 2011

In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Abstract

Extracted data

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer

Abstract

Extracted data

Related items

Related items